Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05897775 · ClinicalTrials.gov registry record · Phase 1

Coordinated Reset Deep Brain Stimulation for Essential Tremor

A Phase 1 study of Essential Tremor and Upper Extremity Essential Tremor, sponsored by University of Minnesota.

Recruiting
Registry status
Phase 1
Development phase
23
Enrollment target
1
Study location

NCT05897775: Recruiting Phase 1 study of Essential Tremor and Upper Extremity Essential Tremor, sponsored by University of Minnesota.

NCT05897775 is a Phase 1 study of Essential Tremor and Upper Extremity Essential Tremor that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 23 participants, below the 402-participant average among 41 other Essential Tremor trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05897775, a Phase 1 study of Essential Tremor and Upper Extremity Essential Tremor, is actively recruiting participants, sponsored by University of Minnesota.

RECRUITING
Registry status
Phase 1
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

Deep brain stimulation (DBS) is a surgical procedure for the treatment of Essential Tremor (ET). A novel approach to current DBS approaches is called coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS that uses continuous high amplitude, high frequency stimulation. This study will evaluate the feasibility, safety and short-term efficacy of thalamic CR-DBS in upper extremity ET. The goal of this study is to evaluate the safety and short-term efficacy of thalamic CR- DBS in ET, including the acute (during CR-DBS) and carryover (following DBS cessation) effects, and compare these to those induced by clinically optimized T-DBS. To achieve our goal, a low-risk, two-phase clinical study will be conducted in patients with upper extremity (UE) ET. The first aim is to identify the spatial location and peak frequency of tremor related oscillatory activities in VIM (Phase I). The second aim is to compare the acute effects of thalamic CR-DBS to clinically optimized T-DBS (Phase II).

Primary Outcome

TETRAS is a rating scale introduced by the Tremor Research Group which has undergone extensive performance evaluations7. The TETRAS Activities of Daily Living Subscale (TETRAS-ADL) rates tremor's impact on activities of daily living, using 12 test items with each item scored from 0-4 (increasing with severity). The TETRAS-ADL total score range is 0-48. The TETRAS performance subscale (TETRAS-P) consists of 16 scored items designed to measure essential tremor of the head, face, voice, upper extr

Interventions

  • DEVICE Deep brain stimulation

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2023-09-11
Est. Completion 2028-12-31
Phase Phase 1
University of Minnesota

966 total trials

What NCT05897775 shows while recruiting

NCT05897775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 402-participant average among 41 other Essential Tremor trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Essential Tremor appearing as the primary indexed condition, and to 1 intervention - of which Deep brain stimulation is the first listed.

NCT05897775 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT05897775 about?

NCT05897775 is a clinical study titled "Coordinated Reset Deep Brain Stimulation for Essential Tremor". Deep brain stimulation (DBS) is a surgical procedure for the treatment of Essential Tremor (ET). A novel approach to current DBS approaches is called coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS that ...

What is the current status of trial NCT05897775?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2023-09-11. Estimated completion is 2028-12-31.

What conditions does trial NCT05897775 study?

This clinical trial studies the following conditions: Essential Tremor, Upper Extremity Essential Tremor.

What interventions are being tested in trial NCT05897775?

The interventions under investigation include: Deep brain stimulation (DEVICE).

Who is sponsoring clinical trial NCT05897775?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05897775 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Essential Tremor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05897775's enrollment target sits among peer trials

23 33rd of 41 higher than 9 of 41 other Essential Tremor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Essential Tremor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05897775, the US trial registry maintained by the National Library of Medicine. NCT05897775 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.